At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 14 enrolled
Drug / intervention
Scopolamine and naltrexone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Safety and Efficacy of Naltrexone and Scopolamine Utilized in Combination in the Treatment of Major Depression: A Double Blinded, Randomized, Controlled Pilot Study
In Brief
A Phase 4 clinical trial evaluating Scopolamine and naltrexone and placebo arm for Depression. Completed, enrolled 14 participants across 1 site.
Detailed Summary
The purpose of this clinical trial is to determine the safety and efficacy of scopolamine utilized in conjunction with naltrexone for the treatment of major depression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartJan 2018
Primary CompletionNov 2018
TodayJul 2026
First PostedDec 29, 2017
Enrollment StartJan 1, 2018
Primary CompletionNov 20, 2018
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.5 years ago
Interventions
Scopolamine and naltrexonedrug
participants will receive scopolamine and naltrexone in buccal drops
placebo armdrug
participants will receive placebo medications